NICE positive for Darzalex combination in newly diagnosed, transplant-eligible myeloma – Johnson & Johnson
NICE(UK): Daratumumab plus bortezomib, lenalidomide and dexamethasone as induction and consolidation treatment, followed by daratumumab plus lenalidomide as maintenance treatment, can be used as an option for untreated multiple… read more.
